BRCA MASTR Dx
A simple, robust and complete CE-IVD validated diagnostic test of breast and ovarian related cancer for detection in MPS The BRCA MASTR™ Dx is a molecular diagnostic assay for the identification of mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers.Multiplicom’s BRCA MASTR™ Dx is ready to use and offers robust performance with minimum hands-on ti…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
A simple, robust and complete CE-IVD validated diagnostic test of breast and ovarian related cancer for detection in MPS
The BRCA MASTR™ Dx is a molecular diagnostic assay for the identification of mutations in the coding regions of the BRCA 1&2 genes in individuals with increased risk for breast, ovarian and/or related cancers.
Multiplicom’s BRCA MASTR™ Dx is ready to use and offers robust performance with minimum hands-on time. All reagents necessary to enable multiplex amplification of 93 amplicons (289-430 bp) are included, for complete exon coverage of all coding sequences of the BRCA 1&2 genes. The assay is compatible with all current Massively Parallel Sequencing (MPS) platforms, giving you the flexibility to choose your preferred method.
BRCA MASTR Dx Advantages:
- Highly efficient workflow - Ready-to-use kit with simple-to-follow protocols for various MPS platforms.
- Uniform coverage - 99.9% amplicons detected > 0.2X mean coverage.
- High target specificity - 99.85% on target bases ~30 of intronic flanking sequence.
- Low amount of DNA required - 20-50 ng per multiplex PCR reaction.
